Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > acasti

<< Previous

Bullboard Posts

Next >>

Post by alanmar1on Aug 14, 2020 2:09pm

286 Views

Post# 31409755

acasti

As a tolerant investor in ACST for many years I wish to raise the following point.

ACST is cash poor and needs a partner.

Have ACST considered approaching one of the large Chinese pharma organizations.

China has enough health problems of it's own for which CarePre could be the answer to justify acquisition and this alone could support a purchase price that would satisfy most, if not all, investors.

Whether or not the FDA issue an NDA or not China would then have a product that would not only help Chinese patients but would also provide them with a product that has worldwide market potential.

<< Previous

Bullboard Posts

Next >>

High-quality lithium projects in Argentina with drilling underway